Preview and readout scenarios ahead of the phase 2 in HS
MoonLake is expected to report phase 2 topline results with sonelokimab in HS at the end of June. With the stock up 130% since our initiation in February and validating data from UCB's bimekizumab, we still believe there is an additional upside to be unlocked for the stock based on our expectations
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.